TWD 21.95
(-3.73%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 944.09 Million TWD | 7.2% |
2022 | 880.66 Million TWD | -0.26% |
2021 | 882.94 Million TWD | 17.6% |
2020 | 750.81 Million TWD | 4.37% |
2019 | 719.35 Million TWD | -2.79% |
2018 | 740.02 Million TWD | -1.98% |
2017 | 754.94 Million TWD | 5.02% |
2016 | 718.88 Million TWD | 3.97% |
2015 | 691.41 Million TWD | -15.86% |
2014 | 821.74 Million TWD | 22.9% |
2013 | 668.63 Million TWD | 33.16% |
2012 | 502.14 Million TWD | 20.08% |
2011 | 418.18 Million TWD | 1.72% |
2010 | 411.13 Million TWD | 15.42% |
2009 | 356.22 Million TWD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 231.74 Million TWD | -10.32% |
2024 Q2 | 234.86 Million TWD | 7.65% |
2023 Q3 | 222.21 Million TWD | 0.21% |
2023 Q4 | 258.41 Million TWD | 16.29% |
2023 FY | 944.09 Million TWD | 7.2% |
2023 Q1 | 242.53 Million TWD | -1.56% |
2023 Q2 | 221.75 Million TWD | -8.57% |
2022 Q2 | 207.27 Million TWD | 0.48% |
2022 Q4 | 246.37 Million TWD | 11.63% |
2022 FY | 880.66 Million TWD | -0.26% |
2022 Q3 | 220.71 Million TWD | 6.48% |
2022 Q1 | 206.29 Million TWD | -16.6% |
2021 Q3 | 214.68 Million TWD | -3.25% |
2021 Q4 | 247.35 Million TWD | 15.22% |
2021 Q1 | 199.01 Million TWD | -9.08% |
2021 Q2 | 221.89 Million TWD | 11.5% |
2021 FY | 882.94 Million TWD | 17.6% |
2020 Q2 | 162.81 Million TWD | 1.03% |
2020 Q1 | 161.15 Million TWD | -8.43% |
2020 FY | 750.81 Million TWD | 4.37% |
2020 Q4 | 218.89 Million TWD | 5.26% |
2020 Q3 | 207.95 Million TWD | 27.72% |
2019 Q3 | 180.04 Million TWD | -2.47% |
2019 FY | 719.35 Million TWD | -2.79% |
2019 Q1 | 180.09 Million TWD | -9.51% |
2019 Q2 | 184.61 Million TWD | 2.51% |
2019 Q4 | 175.99 Million TWD | -2.25% |
2018 Q1 | 172.44 Million TWD | -15.96% |
2018 FY | 740.02 Million TWD | -1.98% |
2018 Q4 | 199.01 Million TWD | 10.75% |
2018 Q3 | 179.69 Million TWD | -4.87% |
2018 Q2 | 188.88 Million TWD | 9.53% |
2017 Q4 | 205.18 Million TWD | 4.4% |
2017 Q1 | 170.93 Million TWD | -9.51% |
2017 Q3 | 196.53 Million TWD | 7.81% |
2017 Q2 | 182.29 Million TWD | 6.64% |
2017 FY | 754.94 Million TWD | 5.02% |
2016 FY | 718.88 Million TWD | 3.97% |
2016 Q1 | 172.37 Million TWD | -8.75% |
2016 Q2 | 190.32 Million TWD | 10.42% |
2016 Q3 | 167.28 Million TWD | -12.11% |
2016 Q4 | 188.89 Million TWD | 12.92% |
2015 Q4 | 188.9 Million TWD | 7.98% |
2015 Q3 | 174.94 Million TWD | 6.2% |
2015 Q2 | 164.72 Million TWD | 1.16% |
2015 Q1 | 162.83 Million TWD | -32.39% |
2015 FY | 691.41 Million TWD | -15.86% |
2014 Q4 | 240.82 Million TWD | 18.85% |
2014 Q3 | 202.62 Million TWD | 10.82% |
2014 Q1 | 195.43 Million TWD | 3.66% |
2014 FY | 821.74 Million TWD | 22.9% |
2014 Q2 | 182.85 Million TWD | -6.44% |
2013 Q4 | 188.54 Million TWD | 7.48% |
2013 FY | 668.63 Million TWD | 33.16% |
2013 Q3 | 175.42 Million TWD | 6.62% |
2013 Q2 | 164.53 Million TWD | 17.41% |
2013 Q1 | 140.13 Million TWD | -7.89% |
2012 Q1 | 105.98 Million TWD | -4.89% |
2012 FY | 502.14 Million TWD | 20.08% |
2012 Q3 | 139.4 Million TWD | 36.76% |
2012 Q2 | 101.93 Million TWD | -3.83% |
2012 Q4 | 152.13 Million TWD | 9.13% |
2011 Q1 | 96.16 Million TWD | -6.9% |
2011 FY | 418.18 Million TWD | 1.72% |
2011 Q2 | 95.51 Million TWD | -0.67% |
2011 Q3 | 115.07 Million TWD | 20.48% |
2011 Q4 | 111.43 Million TWD | -3.16% |
2010 Q3 | 106.42 Million TWD | -8.32% |
2010 FY | 411.13 Million TWD | 15.42% |
2010 Q4 | 103.29 Million TWD | -2.94% |
2010 Q1 | 85.33 Million TWD | 0.0% |
2010 Q2 | 116.08 Million TWD | 36.03% |
2009 FY | 356.22 Million TWD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Excelsior Medical Co., Ltd. | 919.21 Million TWD | -2.707% |
OK Biotech Co., Ltd. | 216.37 Million TWD | -336.329% |
Applied BioCode Corporation | 455.44 Million TWD | -107.293% |